{"id":59787,"date":"2026-06-04T22:48:28","date_gmt":"2026-06-04T13:48:28","guid":{"rendered":"https:\/\/japanir.jp\/en\/company\/company-4594\/"},"modified":"2026-08-23T13:26:59","modified_gmt":"2026-08-23T04:26:59","slug":"company-4594","status":"publish","type":"company","link":"https:\/\/japanir.jp\/en\/company\/company-4594\/","title":{"rendered":"BRIGHTPATH BIOTHERAPEUTICS CO L"},"content":{"rendered":"","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4594","DATE":"2026-01-09","longName":"BrightPath Biotherapeutics Co., Ltd.","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"https:\/\/www.brightpathbio.com","industry":"Biotechnology","sector":"Healthcare","regularMarketPrice":53,"financialCurrency":"","marketCap":5903,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":-11.699999999999999,"epsForward":0,"bookValue":0,"totalRevenue":84000,"OperatingIncome":-1295001000,"operatingMargins":-1541667.8600000001,"NetIncome":-1304951000,"profitMargins":-1553513.1000000001,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":-55.100000000000001,"recommendationMean":0,"recommendationKey":"none","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T03:54:22.793800\", \"ticker\": \"4594\", \"ticker_full\": \"4594.T\", \"company_name\": \"BRIGHTPATH BIOTHERAPEUTICS CO L\", \"analyst_recommendations\": {\"has_data\": true, \"recommendation_key\": \"none\", \"recommendation_mean\": null, \"total_analysts\": null, \"strong_buy\": null, \"buy\": null, \"hold\": null, \"sell\": null, \"strong_sell\": null}, \"target_prices\": {\"has_data\": true, \"current\": 50.0, \"high\": null, \"low\": null, \"mean\": null, \"median\": null}, \"earnings_dates\": {\"has_data\": false}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 3.88, \"institution_pct\": 20.28, \"major_holders\": [{\"label\": \"\", \"value\": 3.88}, {\"label\": \"\", \"value\": 20.28}, {\"label\": \"\", \"value\": 21.1}, {\"label\": \"\", \"value\": 4.0}], \"institutional_holders\": [], \"mutualfund_holders\": []}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1223 to target blood cancers. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. The company was incorporated in 2003 and is headquartered in Kawasaki, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-23T02:00:07.307115\", \"ticker\": \"4594\", \"ticker_full\": \"4594.T\", \"company_name\": \"BRIGHTPATH BIOTHERAPEUTICS CO L\", \"company_info\": {\"name_en\": \"BRIGHTPATH BIOTHERAPEUTICS CO L\", \"long_name\": \"BrightPath Biotherapeutics Co., Ltd.\", \"sector\": \"Healthcare\", \"industry\": \"Biotechnology\", \"website\": \"https:\/\/www.brightpathbio.com\", \"employees\": null, \"country\": \"Japan\", \"city\": \"Kawasaki\", \"address\": \"Kanagawa Prefecture\", \"description\": \"BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets CD39; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neoantigens; and BP1223 to target blood cancers. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. The company was incorporated in 2003 and is headquartered in Kawasaki, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 53.2, \"deviation\": -0.38, \"trend\": \"down\"}, \"ma_25\": {\"ma_value\": 49.56, \"deviation\": 6.94, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 49.44, \"deviation\": 7.2, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 57.12, \"deviation\": -7.22, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2026, \"revenue\": 84000.0, \"revenue_fmt\": \"\u00a584,000\", \"gross_profit\": 54000.0, \"gross_profit_fmt\": \"\u00a554,000\", \"operating_income\": -1295001000.0, \"operating_income_fmt\": \"-\u00a513\u5104\", \"ebit\": -1295001000.0, \"ebit_fmt\": \"-\u00a513\u5104\", \"net_income\": -1304951000.0, \"net_income_fmt\": \"-\u00a513\u5104\", \"eps\": -11.7, \"operating_margin\": -1541667.86, \"total_assets\": 2604864000.0, \"total_assets_fmt\": \"\u00a526\u5104\", \"total_equity\": 2368452000.0, \"total_equity_fmt\": \"\u00a524\u5104\", \"total_debt\": 0.0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 2156198000.0, \"total_cash_fmt\": \"\u00a522\u5104\", \"equity_ratio\": 90.92, \"de_ratio\": 0.0, \"current_ratio\": 15.83, \"operating_cf\": -1365851000.0, \"operating_cf_fmt\": \"-\u00a514\u5104\", \"investing_cf\": -1928000.0, \"investing_cf_fmt\": \"-\u00a51.9M\", \"financing_cf\": 2713507000.0, \"financing_cf_fmt\": \"\u00a527\u5104\", \"free_cf\": -1366442000.0, \"free_cf_fmt\": \"-\u00a514\u5104\", \"net_margin\": -1553513.1, \"roe\": -55.1, \"roa\": -50.1}, {\"year\": 2025, \"revenue\": 1133000.0, \"revenue_fmt\": \"\u00a51.1M\", \"gross_profit\": 1101000.0, \"gross_profit_fmt\": \"\u00a51.1M\", \"operating_income\": -1160918000.0, \"operating_income_fmt\": \"-\u00a512\u5104\", \"ebit\": -1160918000.0, \"ebit_fmt\": \"-\u00a512\u5104\", \"net_income\": -1151149000.0, \"net_income_fmt\": \"-\u00a512\u5104\", \"eps\": -14.12, \"operating_margin\": -102464.08, \"total_assets\": 1120612000.0, \"total_assets_fmt\": \"\u00a511\u5104\", \"total_equity\": 924986000.0, \"total_equity_fmt\": \"\u00a59\u5104\", \"total_debt\": 25000000.0, \"total_debt_fmt\": \"\u00a525.0M\", \"total_cash\": 810470000.0, \"total_cash_fmt\": \"\u00a58\u5104\", \"equity_ratio\": 82.54, \"de_ratio\": 0.03, \"current_ratio\": 8.14, \"operating_cf\": -1250359000.0, \"operating_cf_fmt\": \"-\u00a513\u5104\", \"investing_cf\": -1370000.0, \"investing_cf_fmt\": \"-\u00a51.4M\", \"financing_cf\": 1004840000.0, \"financing_cf_fmt\": \"\u00a510\u5104\", \"free_cf\": -1251729000.0, \"free_cf_fmt\": \"-\u00a513\u5104\", \"net_margin\": -101601.85, \"roe\": -124.45, \"roa\": -102.73}, {\"year\": 2024, \"revenue\": 72000.0, \"revenue_fmt\": \"\u00a572,000\", \"gross_profit\": 54000.0, \"gross_profit_fmt\": \"\u00a554,000\", \"operating_income\": -1155079000.0, \"operating_income_fmt\": \"-\u00a512\u5104\", \"ebit\": -1155079000.0, \"ebit_fmt\": \"-\u00a512\u5104\", \"net_income\": -1168082000.0, \"net_income_fmt\": \"-\u00a512\u5104\", \"eps\": -18.21, \"operating_margin\": -1604276.39, \"total_assets\": 1230257000.0, \"total_assets_fmt\": \"\u00a512\u5104\", \"total_equity\": 978986000.0, \"total_equity_fmt\": \"\u00a510\u5104\", \"total_debt\": 112500000.0, \"total_debt_fmt\": \"\u00a51\u5104\", \"total_cash\": 1057360000.0, \"total_cash_fmt\": \"\u00a511\u5104\", \"equity_ratio\": 79.58, \"de_ratio\": 0.11, \"current_ratio\": 6.18, \"operating_cf\": -1156920000.0, \"operating_cf_fmt\": \"-\u00a512\u5104\", \"investing_cf\": -7648000.0, \"investing_cf_fmt\": \"-\u00a57.6M\", \"financing_cf\": 690959000.0, \"financing_cf_fmt\": \"\u00a57\u5104\", \"free_cf\": -1164568000.0, \"free_cf_fmt\": \"-\u00a512\u5104\", \"net_margin\": -1622336.11, \"roe\": -119.32, \"roa\": -94.95}, {\"year\": 2023, \"revenue\": 5280000.0, \"revenue_fmt\": \"\u00a55.3M\", \"gross_profit\": 3384000.0, \"gross_profit_fmt\": \"\u00a53.4M\", \"operating_income\": -1467059000.0, \"operating_income_fmt\": \"-\u00a515\u5104\", \"ebit\": -1483672000.0, \"ebit_fmt\": \"-\u00a515\u5104\", \"net_income\": -1485633000.0, \"net_income_fmt\": \"-\u00a515\u5104\", \"eps\": -24.9, \"operating_margin\": -27785.21, \"total_assets\": 1701444000.0, \"total_assets_fmt\": \"\u00a517\u5104\", \"total_equity\": 1567539000.0, \"total_equity_fmt\": \"\u00a516\u5104\", \"total_debt\": 0.0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 1530969000.0, \"total_cash_fmt\": \"\u00a515\u5104\", \"equity_ratio\": 92.13, \"de_ratio\": 0.0, \"current_ratio\": 21.57, \"operating_cf\": -1204401000.0, \"operating_cf_fmt\": \"-\u00a512\u5104\", \"investing_cf\": -1760000.0, \"investing_cf_fmt\": \"-\u00a51.8M\", \"financing_cf\": 432104000.0, \"financing_cf_fmt\": \"\u00a54\u5104\", \"free_cf\": -1206161000.0, \"free_cf_fmt\": \"-\u00a512\u5104\", \"net_margin\": -28136.99, \"roe\": -94.77, \"roa\": -87.32}, {\"year\": 2022, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 0, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [], \"has_data\": false}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-59787","company","type-company","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BRIGHTPATH BIOTHERAPEUTICS CO L - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4594\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4594\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4594\/\",\"name\":\"BRIGHTPATH BIOTHERAPEUTICS CO L - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-06-04T13:48:28+00:00\",\"dateModified\":\"2026-08-23T04:26:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4594\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4594\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4594\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BRIGHTPATH BIOTHERAPEUTICS CO L\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BRIGHTPATH BIOTHERAPEUTICS CO L - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4594\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4594\/","url":"https:\/\/japanir.jp\/en\/company\/company-4594\/","name":"BRIGHTPATH BIOTHERAPEUTICS CO L - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-06-04T13:48:28+00:00","dateModified":"2026-08-23T04:26:59+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4594\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4594\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4594\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"BRIGHTPATH BIOTHERAPEUTICS CO L"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company\/59787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/company"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/company"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=59787"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=59787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}